Sign In
Buy OCGN
$1.22
+0.0100 (+0.83%)
At Close: Jun 15, 2026
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
11:00am, Friday, 24'th May 2024
LOS ANGELES , May 24, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit again
1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole
08:10am, Friday, 24'th May 2024
Ocugen is inching closer towards an approval with (alleged) blockbuster potential. The rest of the company's pipeline looks reasonably deep for its size.
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
12:00pm, Thursday, 23'rd May 2024
LOS ANGELES , May 23, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against
OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit
11:00am, Wednesday, 22'nd May 2024
BENSALEM, Pa. , May 22, 2024 /PRNewswire/ -- Law Offices of Howard G.
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
09:00am, Wednesday, 22'nd May 2024
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 10, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of in
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who p
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Ocugen, Inc. (“Ocugen” or the “Company”
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
07:00am, Monday, 20'th May 2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
11:00am, Sunday, 19'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
11:00am, Saturday, 18'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com
NEW YORK , May 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024,
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
11:00am, Friday, 17'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
11:00am, Thursday, 16'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm
10:00am, Wednesday, 15'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel ge
